INVESTOR ALERT: Levi & Korsinsky, LLP Commences an Investigation of the Board of Directors of Vision-Sciences, Inc. In Connec...
February 02 2015 - 2:57PM
Business Wire
Levi & Korsinsky is commencing an investigation into the
Board of Directors of Vision-Sciences, Inc. (“Vision-Sciences” or
“the Company”) (NasdaqCM:VSCI) in connection with possible breaches
of fiduciary duty and other violations of state law in connection
with the merger of the Company to Uroplasty, Inc.
(NasdaqCM:UPI).
Click here to learn more about the investigation:
http://zlk.9nl.com/vision-sciences-vsci.
Upon completion of the merger, Vision-Sciences shareholders will
own only 37.5% of the post-merger entity. The investigation
concerns whether the Board of Vision-Sciences is acting in
shareholders’ best interest by agreeing to this transaction. The
new company will conduct business as Cogentix Medical, Inc., and
its Board will consist of 5 representatives from Uroplasty’s
existing board and just three representatives from Vision-Sciences’
existing board.
If you own Vision-Sciences common stock and wish to obtain
additional information, please contact Joseph E. Levi, Esq. either
via email at jlevi@zlk.com or by telephone at (212) 363-7500,
toll-free: (877) 363-5972, or visit
http://zlk.9nl.com/vision-sciences-vsci.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, Connecticut and Washington D.C. The firm’s
attorneys have extensive expertise in prosecuting securities
litigation involving financial fraud, representing investors
throughout the nation in securities and shareholder lawsuits. For
more information, please feel free to contact any of the attorneys
listed below. Attorney advertising. Prior results do not guarantee
similar outcomes.
Levi & Korsinsky, LLPJoseph Levi, Esq.Eduard Korsinsky,
Esq.Tel: 212-363-7500Toll Free: 877-363-5972Fax:
866-367-6510www.zlk.com
Cognyte Software (NASDAQ:CGNT)
Historical Stock Chart
From Apr 2024 to May 2024
Cognyte Software (NASDAQ:CGNT)
Historical Stock Chart
From May 2023 to May 2024